Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29357996 | 0.95 | MDM2 (0.46) | MDM2PTPN1MDM4TP53 | |
| SCHEMBL21175068 | 0.93 | MDM2 (0.52) | MDM2PTPN1MDM4TP53BACE1 | |
| SCHEMBL21175067 | 0.93 | MDM2 (0.52) | MDM2PTPN1MDM4TP53BACE1 | |
| SCHEMBL29360735 | 0.91 | EPHX2 (0.47) | MDM2PTPN1 | |
| SCHEMBL30643729 | 0.90 | MDM2 (0.49) | MDM2PTPN1BACE1 | |
| SCHEMBL29115023 | 0.90 | MDM2 (0.49) | MDM2PTPN1BACE1 | |
| SCHEMBL29115025 | 0.90 | MDM2 (0.49) | MDM2PTPN1BACE1 | |
| SCHEMBL10078351 | 0.88 | MDM2 (0.48) | MDM2PTPN1MDM4TP53TLR2 | |
| SCHEMBL16093056 | 0.88 | MDM2 (0.48) | MDM2PTPN1MDM4TP53TLR2 | |
| SCHEMBL29363204 | 0.88 | MDM2 (0.44) | MDM2PTPN1MDM4TP53BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289848-A1 | PEPTIDOMIMETIC INHIBITORS OF B-CATENIN/TCF PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2025-09-18 | — | — | US | disclosed |
| US-12269899-B2 | Peptidomimetic inhibitors of β-catenin/Tcf protein-protein interaction | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20220024977-A1 | PEPTIDOMIMETIC INHIBITORS OF B-CATENIN/TCF PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289848-A1 | PEPTIDOMIMETIC INHIBITORS OF B-CATENIN/TCF PROTEIN-PROTEIN INTERACTION | CTNNB1, CTNNBL1, CTNND1 | MDM2 2853/4885PTPN1 2059/4885MDM4 2619/4885 |
| US-12269899-B2 | Peptidomimetic inhibitors of β-catenin/Tcf protein-protein interaction | CTNNB1, CTNNBL1, CTNND1 | MDM2 2368/4885PTPN1 2253/4885MDM4 2057/4885 |
| US-20220024977-A1 | PEPTIDOMIMETIC INHIBITORS OF B-CATENIN/TCF PROTEIN-PROTEIN INTERACTION | CTNNB1, CTNNBL1, CTNND1 | MDM2 2853/4885PTPN1 2059/4885MDM4 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.